A Multicenter, Randomized, Open-label, Controlled Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Sinapultide (Primary)
- Indications Neonatal respiratory distress syndrome
- Focus Adverse reactions
- Sponsors Windtree Therapeutics
- 15 Aug 2017 Status changed from recruiting to discontinued as per sponsor decision to terminate after 3 dosing groups.
- 22 Jul 2017 This trial has been discontinued in Poland (end date: 2017-07-07)
- 21 Apr 2017 Planned End Date changed from 1 Mar 2017 to 31 May 2017.